Overview
CRVS market data
Price History
CRVS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.38 – $26.95 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 9.40.
Company News
Corvus Pharma Q2 EPS $(0.19) Misses $(0.17) EstimateBenzinga · Aug 6, 2026, 8:14 PM
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?The Motley Fool · Jun 23, 2026, 8:01 PM
Corvus Pharma Participates In New $13.5M Financing For Angel PharmaceuticalsBenzinga · Jun 9, 2026, 11:40 AM